Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities). $525.0 million convertible senior notes issued, increasing Travere’s long-term financing capacity.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $525.0 million convertible senior notes issued, increasing Travere’s long-term financing capacity
- 0.50% coupon and 2032 maturity imply relatively low-cost capital with extended repayment timing
- Convertible structure may create future share dilution if noteholders convert
- Proceeds support corporate liquidity and strategic flexibility, though specific use is not stated in the excerpt
Item 3.02 · Unregistered Sales of Equity Securities
- Up to 11,729,182 common shares issuable upon conversion of notes
- Initial conversion rate of 22.3413 shares per $1,000 principal amount
- Unregistered issuance may rely on Securities Act Section 3(a)(9) exemption
- Potential dilution for existing shareholders, subject to anti-dilution adjustments
Item 8.01 · Other Events
- $475.0M senior notes offering, with underwriters’ $50.0M over-allotment option
- Approximately $508.5M expected net proceeds, expanding funding for commercialization and research
- $350.9M cash planned to repurchase approximately $221.4M of 2.25% convertible notes due 2029
- Refinancing reduces 2029 convertible debt but uses most proceeds for repurchase consideration and accrued interest
- Remaining proceeds targeted for general corporate purposes, including clinical trials, capital expenditures and working capital
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.